Online inquiry

IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1679MR)

This product GTTS-WQ1679MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL1B gene. The antibody can be applied in Atherosclerosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000576.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3553
UniProt ID P01584
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1679MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3737MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ14076MR IVTScrip™ mRNA-Anti-DLL4, REGN-421(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-421
GTTS-WQ12510MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ9186MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ5726MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ5341MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ7489MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GC-1008
GTTS-WQ12313MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW